Delivery Order SPE2DB22D1106-SPE2DB25FFEM8
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,935.74 to AmerisourceBergen Drug Corp for ADDYI (flibanserin) 100 mg tablets in quantities of 30 on August 15, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price delivery order, which is not set-aside, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The product...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $5,675.92 for ADDYI (flibanserin) 100 mg tablets in quantities of 30 units. This contract, issued on August 26, 2025, with an ultimate completion date of August 27, 2025, was competitively awarded without set-aside designation under a firm fixed price structure. The pharmaceutical product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $6,091.21 delivery order on September 8, 2025, for ADDYI (flibanserin) 100 mg tablets in quantities of 30s. This is a firm fixed-price, non-set-aside contract with a completion date of September 9, 2025, to be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a $5,959.27 delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of ADDYI (flibansergin) 100 mg tablets in quantities of 30 units. This is a firm fixed price, competitively awarded contract with no set-aside designation, scheduled for ultimate completion on September 8, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a $5,184.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ADDYI (flibanserina) 100 mg tablets in quantities of 30 units. This delivery order, issued on July 21, 2025, with an ultimate completion date of July 22, 2025, represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The award was made through open competition with no set-aside designation. AmerisourceBergen, a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for ADDYI (flibanserene) 100 mg tablets in quantities of 30 units, with a ceiling value of $41,739.01. This firm fixed price delivery order, awarded September 4, 2025, with ultimate completion by September 5, 2025, represents a competitive award with no set-aside designation. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency has awarded a delivery order valued at $4,889.15 to AmerisourceBergen Drug Corp for the supply of ADDYI 100 mg tablets in quantities of 30 units. This non-set-aside, competitively awarded contract carries a firm fixed price structure with an ultimate completion date of June 2, 2025. The award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of ADDYI (flibanserins) 100 mg tablets in quantities of 30 count, valued at $3,654.47. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for completion by September 25, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,465.19 to AmerisourceBergen Drug Corp for the supply of ADDYI (flibanserin) 100 mg tablets in quantities of 30 units. This non-competitive, firm fixed-price delivery order was awarded on September 23, 2025, with an ultimate completion date of September 24, 2025. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania, which serves as the company's corporate headquarters and primary...
- The Defense Logistics Agency awarded a delivery order valued at $1,410.28 to AmerisourceBergen Drug Corp for ADDYI 100 mg tablets (30-count units) on September 5, 2025, with an ultimate completion date of September 8, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its headquarters...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFEM8Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,935.74 to AmerisourceBergen Drug Corp for ADDYI (flibansergin) 100 mg tablets in quantities of 30 units. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of August 22, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is performing work at its corporate office location. This delivery order is issued under the company's existing indefinite delivery contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and running through December 2026. AmerisourceBergen Drug Corp serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Health Agency and other government healthcare entities. The company's pharmaceutical portfolio under its DLA contract encompasses specialty medications, brand-name and generic drugs, vaccines, and related medical supplies across multiple therapeutic domains. The current delivery order for ADDYI represents a small-value transaction within the company's extensive contract portfolio with DLA, demonstrating its capability to fulfill specialized pharmaceutical needs for federal healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 8/21/25 |